arrow
F

Federica Gaiani

university of parma
H指数:25
被引数:2,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Optimizing branch-duct intraductal papillary mucinous neoplasms surveillance: Data-driven dimensional grouping for risk stratification and cost-effectiveness

基于数据驱动的维度分组优化分支导管型胰腺囊性肿瘤的监测:风险评估与成本效益分析

2026-05-280
PRE
Comparative Effectiveness and Safety of Tofacitinib, Filgotinib, and Upadacitinib in Ulcerative Colitis: A Multicenter Real-World Cohort Study

托法替布、菲洛吉替尼和乌帕替尼治疗溃疡性结肠炎的疗效和安全性比较:一项多中心真实世界队列研究

2026-05-090
OAAI
Transition of Pediatric-Onset Inflammatory Bowel Disease to Adult Care: A Multicenter Italian Cohort Study

儿科起病炎症性肠病向成人护理的过渡:一项意大利多中心队列研究

2026-01-010
PRE
Upadacitinib’s Effectiveness and Safety as a Second- or Third-Line Therapy in Patients with Ulcerative Colitis: Data from a Real-World Study

乌帕替尼作为溃疡性结肠炎患者二线或三线治疗的有效性与安全性:真实世界研究数据

2025-11-030
OAAI
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study

Tursi, A.; Mocci, G.; Costa, F.; Ceccarelli, L.; Savarino, E.; De Barba, C.; Mucherino, C.; D’antonio, E.; Montesano, L.; Marzo, M.; 等. Filgotinib 在溃疡性结肠炎患者中作为二线或三线治疗的有效性与安全性:真实世界研究数据. Intest. Res. 2025, 已接收. [CrossRef] [PubMed]

2025-09-011
PRE
P0634 Upadacitinib Effectiveness And Safety In Patients With Ulcerative Colitis: Data From A Real-World Study
2025-01-220
PRE
Filgotinib effectiveness and safety as second or third-line therapy in patients with ulcerative colitis: data from a real-world study
2025-01-220
PRE
Long-Term Effectiveness and Safety of Ustekinumab in Crohn's Disease: Results from a Large Real-Life Cohort Study
2024-11-271
OAAI
Ustekinumab safety and effectiveness in patients with ulcerative colitis: results from a large real-life study
2024-01-256
PRE
Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study
2023-03-026
PRE
Notch-Jagged1 signaling and response to bevacizumab therapy in advanced colorectal cancer: A glance to radiomics or back to physiopathology?

Notch-Jagged1信号和贝伐单抗治疗晚期结直肠癌的反应: 对放射组学的一瞥还是回到病理生理学?

2023-02-284
OAAI
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy
2021-12-273
PREAI